A Phase III Randomized Trial of MK-3475 (Pembrolizumab) Versus Standard Treatment in Subjects With Recurrent or Metastatic Head and Neck Cancer

Trial Profile

A Phase III Randomized Trial of MK-3475 (Pembrolizumab) Versus Standard Treatment in Subjects With Recurrent or Metastatic Head and Neck Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs Pembrolizumab (Primary) ; Cetuximab; Docetaxel; Methotrexate
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYNOTE-040
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 14 Mar 2018 According to a Merck & Co media release, results from the study will be present at the American Association for Cancer Research (AACR) Annual Meeting 2018.
    • 11 Sep 2017 Complete results from this trial will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress, as reported in a Merck & Co media release
    • 11 Sep 2017 Results published in the Merck & Co Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top